Director/PDMR Shareholding
Oxford Biomedica plc announced that Chief Legal Officer Natalie Walter exercised 3,057 SAYE options at £2.944 per share and sold these shares for £6.3939 each, while Chief People Officer Lisa Doman exercised 10,591 DBP options at nil cost and 2,709 ESOS options at £4.966 per share, subsequently selling a total of 13,300 shares at an average price of £6.35 per share. These transactions involved the exercise and disposal of shares by individuals discharging managerial responsibilities within the company.
Select text to share a quote on X · sign in to keep highlights & notes in your OXB notes
Oxford, UK - 13 May 2026: OXB (LSE: OXB) (the "Company"), a global quality and innovation-led cell and gene therapy CDMO, today announces that Natalie Walter, Chief Legal Officer and Group Company Secretary has exercised 3,057 Save As You Earn (SAYE) 2022 options at an exercise price of £2.944 per share on 12 May 2026 and disposed of 3,057 shares at an average price of £6.3939 per share on 12 May 2026.
In addition, Lisa Doman, Chief People Officer, has exercised 10,591 Deferred Bonus Plan (DBP) options and 2,709 Executive Share Option Scheme (ESOS) options at an exercise price of £nil per share and £4.966 per share respectively on 12 May 2026 and sold 13,300 shares at an average price of £6.35 per share on 12 May 2026.
| 1. | Details of the p erson discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA") | |||||
| a) | Is this a PDMR or PCA submission | Submission for PDMR | ||||
| b) | Name of natural person | Natalie Walter | ||||
| c) | Legal person | |||||
| 2. | Reason for the notification | |||||
| a) | Position/status | Chief Legal Officer and Group Company Secretary | ||||
| b) | Initial notification/ amendment | Initial Notification | ||||
| 3. | Details of the Issuer | |||||
| a) | Full name of the entity | Oxford Biomedica plc | ||||
| b) | LEI code | 213800S1GVQNXQ15K851 | ||||
| a) | Date of the transaction | 12 May 2026 | ||||
| b) | Description of the financial instrument | Share | ||||
| c) | Identification code | ISIN: GB00BDFBVT43 | ||||
| d) | Nature of the transaction | Exercise of SAYE 2022 Options | ||||
| e) | Place of the transaction | Outside the trading venue | ||||
| f) | Currency | GBP - British pound | ||||
| g) | Price(s) and volumes(s) |
| ||||
| h) | Aggregated information - Aggregate volume - Price - Aggregated total | 3,057 £2.944 £8,999.81 | ||||
| 1. | Details of the p erson discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA") | |||||
| a) | Is this a PDMR or PCA submission | Submission for PDMR | ||||
| b) | Name of natural person | Natalie Walter | ||||
| c) | Legal person | |||||
| 2. | Reason for the notification | |||||
| a) | Position/status | Chief Legal Officer and Group Company Secretary | ||||
| b) | Initial notification/ amendment | Initial Notification | ||||
| 3. | Details of the Issuer | |||||
| a) | Full name of the entity | Oxford Biomedica plc | ||||
| b) | LEI code | 213800S1GVQNXQ15K851 | ||||
| a) | Date of the transaction | 12 May 2026 | ||||
| b) | Description of the financial instrument | Share | ||||
| c) | Identification code | ISIN: GB00BDFBVT43 | ||||
| d) | Nature of the transaction | Sale of shares | ||||
| e) | Place of the transaction | London Stock Exchange, Main Market (XLON) | ||||
| f) | Currency | GBP - British pound | ||||
| g) | Price(s) and volumes(s) |
| ||||
| h) | Aggregated information - Aggregate volume - Price - Aggregated total | 3,057 £6.3939 £19,546.15 | ||||
| 1. | Details of the p erson discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA") | |||||
| a) | Is this a PDMR or PCA submission | Submission for PDMR | ||||
| b) | Name of natural person | Lisa Doman | ||||
| c) | Legal person | |||||
| 2. | Reason for the notification | |||||
| a) | Position/status | Chief People Officer | ||||
| b) | Initial notification/ amendment | Initial Notification | ||||
| 3. | Details of the Issuer | |||||
| a) | Full name of the entity | Oxford Biomedica plc | ||||
| b) | LEI code | 213800S1GVQNXQ15K851 | ||||
| a) | Date of the transaction | 12 May 2026 | ||||
| b) | Description of the financial instrument | Share | ||||
| c) | Identification code | ISIN: GB00BDFBVT43 | ||||
| d) | Nature of the transaction | Exercise of DBP options | ||||
| e) | Place of the transaction | Outside the trading venue | ||||
| f) | Currency | GBP - British pound | ||||
| g) | Price(s) and volumes(s) | Price(s) Volume(s) £nil 5,295 £nil 5,296 | ||||
| h) | Aggregated information - Aggregate volume - Price - Aggregated total | 10,591 £nil £nil | ||||
| 1. | Details of the p erson discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA") | |||||
| a) | Is this a PDMR or PCA submission | Submission for PDMR | ||||
| b) | Name of natural person | Lisa Doman | ||||
| c) | Legal person | |||||
| 2. | Reason for the notification | |||||
| a) | Position/status | Chief People Officer | ||||
| b) | Initial notification/ amendment | Initial Notification | ||||
| 3. | Details of the Issuer | |||||
| a) | Full name of the entity | Oxford Biomedica plc | ||||
| b) | LEI code | 213800S1GVQNXQ15K851 | ||||
| a) | Date of the transaction | 12 May 2026 | ||||
| b) | Description of the financial instrument | Share | ||||
| c) | Identification code | ISIN: GB00BDFBVT43 | ||||
| d) | Nature of the transaction | Exercise of ESOS Options | ||||
| e) | Place of the transaction | Outside the trading venue | ||||
| f) | Currency | GBP - British pound | ||||
| g) | Price(s) and volumes(s) |
| ||||
| h) | Aggregated information - Aggregate volume - Price - Aggregated total | 2,709 £4.966 £13,452.89 | ||||
| 1. | Details of the p erson discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA") | |||||
| a) | Is this a PDMR or PCA submission | Submission for PDMR | ||||
| b) | Name of natural person | Lisa Doman | ||||
| c) | Legal person | |||||
| 2. | Reason for the notification | |||||
| a) | Position/status | Chief People Officer | ||||
| b) | Initial notification/ amendment | Initial Notification | ||||
| 3. | Details of the Issuer | |||||
| a) | Full name of the entity | Oxford Biomedica plc | ||||
| b) | LEI code | 213800S1GVQNXQ15K851 | ||||
| a) | Date of the transaction | 12 May 2026 | ||||
| b) | Description of the financial instrument | Share | ||||
| c) | Identification code | ISIN: GB00BDFBVT43 | ||||
| d) | Nature of the transaction | Sale of Shares | ||||
| e) | Place of the transaction | London Stock Exchange, Main Market (XLON) | ||||
| f) | Currency | GBP - British pound | ||||
| g) | Price(s) and volumes(s) |
| ||||
| h) | Aggregated information - Aggregate volume - Price - Aggregated total | 13,300 £6.35 £84,455.00 |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.